Published in PLoS One on December 09, 2013
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet (1996) 13.20
Osteoporosis prevention, diagnosis, and therapy. JAMA (2001) 12.60
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA (1999) 11.23
Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med (1995) 10.99
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med (2001) 9.57
Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med (2007) 7.38
Esophagitis associated with the use of alendronate. N Engl J Med (1996) 4.89
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int (2000) 4.85
Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf (2006) 4.64
Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med (1992) 4.19
Non-steroidal anti-inflammatory drugs and peptic ulcers. BMJ (1990) 4.10
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res (2004) 4.04
Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med (2000) 3.26
Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. Pharmacoepidemiol Drug Saf (2010) 2.57
Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med (2000) 2.46
Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab (2000) 2.34
Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med (1998) 2.32
Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med (2003) 2.24
Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Lancet (1988) 2.13
Nimodipine neuroprotection in cardiac valve replacement: report of an early terminated trial. Stroke (1996) 2.10
Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int (1999) 1.98
The impact of research quality and study design on epidemiologic estimates of the effect of nonsteroidal anti-inflammatory drugs on upper gastrointestinal tract disease. Arch Intern Med (1992) 1.98
Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc (2002) 1.97
Peptic ulcer disease. Am Fam Physician (2007) 1.73
Immeasurable time bias in observational studies of drug effects on mortality. Am J Epidemiol (2008) 1.73
Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut (2000) 1.69
Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int (2000) 1.62
Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Saf (2004) 1.56
Application of lag-time into exposure definitions to control for protopathic bias. Pharmacoepidemiol Drug Saf (2007) 1.44
Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. Circulation (2011) 1.33
Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding? Aliment Pharmacol Ther (2005) 1.27
Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. J Clin Endocrinol Metab (1998) 1.22
Exercise interventions: defusing the world's osteoporosis time bomb. Bull World Health Organ (2004) 1.17
What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates. Dig Dis Sci (2002) 1.14
Fibrate/Statin initiation in warfarin users and gastrointestinal bleeding risk. Am J Med (2010) 1.11
Bleeding peptic ulcer in the elderly: risk factors and prevention strategies. Drugs Aging (2007) 1.10
Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clin Proc (2002) 1.07
Statin treatment and mortality in bacterial infections--a systematic review and meta-analysis. PLoS One (2010) 1.05
Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis. J Clin Endocrinol Metab (1994) 1.03
Positive predictive value of ICD-9th codes for upper gastrointestinal bleeding and perforation in the Sistema Informativo Sanitario Regionale database. J Clin Epidemiol (1999) 1.01
Gastric and duodenal safety of daily alendronate. Arch Intern Med (2002) 0.94
Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis. J Bone Miner Res (2004) 0.92
Multiple vertebral fractures are associated with refractory reflux esophagitis in postmenopausal women. J Bone Miner Metab (2005) 0.91
Risk of upper gastrointestinal bleeding with oral bisphosphonates and non steroidal anti-inflammatory drugs: a case-control study. Aliment Pharmacol Ther (2009) 0.89
Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension. J Bone Miner Res (2002) 0.86
Analysis of the risk factors and their combinations in acute gastroduodenal ulcer bleeding: a case-control study. Scand J Gastroenterol (2007) 0.86
Comparative gastrointestinal safety of weekly oral bisphosphonates. Osteoporos Int (2009) 0.85
Retracted Beneficial effect of intermittent cyclical etidronate therapy in hemiplegic patients following an acute stroke. J Bone Miner Res (2000) 0.83
Lack of effect of intravenous pamidronate on fracture incidence and bone mineral density after orthotopic liver transplantation. J Hepatol (2002) 0.83
Bisphosphonate increases risk of gastroduodenal ulcer in rheumatoid arthritis patients on long-term nonsteroidal antiinflammatory drug therapy. J Gastroenterol (2009) 0.81
Upper gastrointestinal adverse events and cyclical etidronate. Am J Med (1997) 0.81
Beneficial effect of etidronate therapy in immobilized hip fracture patients. Am J Phys Med Rehabil (2004) 0.79
Intermittent oral disodium pamidronate in established osteoporosis: a 2 year double-masked placebo-controlled study of efficacy and safety. Osteoporos Int (2000) 0.79
Role of oral pamidronate in preventing bone loss in postmenopausal women. Osteoporos Int (1996) 0.76
The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol (2003) 1.92
A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. J Card Fail (2003) 1.60
Hormone replacement therapy is associated with improved survival in women with advanced heart failure. J Am Coll Cardiol (2003) 1.48
Impact of nonfatal myocardial infarction on outcomes in patients with advanced heart failure and the effect of bucindolol therapy. Am J Cardiol (2005) 0.80
Statins use and the risk of all and subtype hematological malignancies: a meta-analysis of observational studies. Cancer Med (2015) 0.79
User-only design to assess drug effectiveness in clinical practice: application to bisphosphonates and secondary prevention of fractures. Pharmacoepidemiol Drug Saf (2014) 0.77